Chemed Corp. (NYSE:CHE) issued an update on its FY17 earnings guidance on Thursday morning. The company provided earnings per share guidance of $8.35-$8.40 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $8.19.
Shares of Chemed Corp. (NYSE CHE) opened at C$231.12 on Friday. The company has a quick ratio of 0.48, a current ratio of 0.50 and a debt-to-equity ratio of 0.15. Chemed Corp. has a 12 month low of C$143.87 and a 12 month high of C$235.96. The stock has a market capitalization of $3,690.06, a P/E ratio of 28.46, a price-to-earnings-growth ratio of 4.89 and a beta of 1.14.
Chemed Corp. (NYSE:CHE) last released its earnings results on Thursday, October 26th. The company reported C$2.15 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of C$2.00 by C$0.15. The firm had revenue of C$417.40 million for the quarter, compared to the consensus estimate of C$414.34 million. Chemed Corp. had a return on equity of 27.69% and a net margin of 4.62%. The company’s revenue for the quarter was up 6.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.73 EPS. sell-side analysts expect that Chemed Corp. will post 4.73 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 4th. Shareholders of record on Monday, November 13th will be given a $0.28 dividend. This represents a $1.12 annualized dividend and a yield of 0.48%. The ex-dividend date is Friday, November 10th. Chemed Corp.’s dividend payout ratio (DPR) is presently 24.89%.
CHE has been the topic of several research analyst reports. TheStreet downgraded Chemed Corp. from a b+ rating to a c+ rating in a research report on Tuesday, July 25th. Oppenheimer Holdings, Inc. upped their target price on Chemed Corp. from $200.00 to $220.00 and gave the stock an outperform rating in a report on Thursday, July 27th. Zacks Investment Research upgraded Chemed Corp. from a hold rating to a buy rating and set a $226.00 target price for the company in a report on Friday, July 28th. Royal Bank of Canada reiterated a hold rating and issued a $209.00 target price on shares of Chemed Corp. in a report on Monday, July 31st. Finally, BidaskClub cut Chemed Corp. from a buy rating to a hold rating in a research note on Wednesday, August 2nd. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The stock presently has a consensus rating of Hold and a consensus price target of C$236.00.
In related news, VP Naomi C. Dallob sold 1,900 shares of the firm’s stock in a transaction dated Wednesday, November 8th. The stock was sold at an average price of C$231.00, for a total transaction of C$438,900.00. Following the sale, the vice president now directly owns 10,426 shares of the company’s stock, valued at C$2,408,406. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Spencer S. Lee sold 1,000 shares of the firm’s stock in a transaction dated Friday, September 1st. The stock was sold at an average price of C$197.46, for a total value of C$197,460.00. Following the sale, the insider now directly owns 37,809 shares in the company, valued at C$7,465,765.14. The disclosure for this sale can be found here. Over the last quarter, insiders sold 15,650 shares of company stock valued at $3,480,193. 4.90% of the stock is currently owned by company insiders.
ILLEGAL ACTIVITY WARNING: “Chemed Corp. (CHE) Releases FY17 Earnings Guidance” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece of content on another website, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece of content can be accessed at https://www.dispatchtribunal.com/2017/11/12/chemed-corp-che-issues-fy17-earnings-guidance.html.
Chemed Corp. Company Profile
Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.
Receive News & Ratings for Chemed Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed Corp. and related companies with MarketBeat.com's FREE daily email newsletter.